Tango Therapeutics Ends TNG348 Program

Tango Therapeutics, Inc., a biotechnology firm focused on advancing precision cancer treatments, has decided to discontinue its phase 1/2 clinical trial for TNG348, a USP1 inhibitor. The decision comes after the observation of significant liver toxicity in patients who participated in the initial study cohorts.

According to Barbara Weber, M.D., President and CEO of Tango Therapeutics, patient safety is paramount. The emerging data from the TNG348 dose escalation study revealed concerning liver function abnormalities in patients who had been on the treatment for more than eight weeks. Dr. Weber stated, "While it is disappointing to halt the development of TNG348, it is the correct decision based on the current data."

TNG348 was being investigated for its safety, pharmacokinetics, pharmacodynamics, and efficacy both as a standalone treatment and in combination with olaparib, a PARP inhibitor. The target patient group included those with BRCA1/2-mutant and other homologous recombination deficient (HRD+) cancers. Due to the Grade 3 and 4 liver function abnormalities observed, the program was terminated before any patient could receive the combination treatment of TNG348 and olaparib.

Even as the TNG348 program is being discontinued, Tango Therapeutics continues to move forward with other key projects. The company is redirecting its focus and resources towards its PRMT5 and CoREST clinical programs. Dr. Weber expressed confidence in providing a detailed clinical update on TNG908 and TNG462 later this year. Furthermore, the company has extended its cash runway into 2027, ensuring the continuation of its other clinical initiatives.

Tango Therapeutics leverages the genetic principle of synthetic lethality to develop targeted cancer therapies, focusing on novel areas such as tumor suppressor gene loss and immune evasion mechanisms in cancer cells.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!